Detalhe da pesquisa
1.
Subcutaneous anti-COVID-19 hyperimmune immunoglobulin for prevention of disease in asymptomatic individuals with SARS-CoV-2 infection: a double-blind, placebo-controlled, randomised clinical trial.
EClinicalMedicine
; 57: 101898, 2023 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-36936402